Product News

Seegene's product news

Obtained CE-IVD marking for assays that detects MTB and Multi-Drug Resistance and Extensively Drug Resistance

Tuberculosis Allplex™ MTB/MDR/XDRe Detection 2018.10.29

Seegene has received CE-IVD mark under European Union on In Vitro Diagnostics Medical Devices for Allplex™ MTB/MDR/XDRe Detection, Allplex™ MTB/MDRe Detection, Allplex™ MTB/XDRe Detection.

Based on Seegene's proprietary DPO™ and TOCE™ technology, these assays are multiplex real-time PCR assay that detects and identifies Mycobacterium tuberculosis (MTB) and 25 mutations associated with Multi-Drug Resistance (MDR) and 13 mutations associated with Extensively Drug Resistance (XDR). These assays enable to deliver MTB and Drug-resistant TB result in one day, which helps effective management of tuberculosis.

Previous Next List
Previous Obtained CE-IVD marking for Allplex™ MG & AziR Assay 2019.01.22
Next Obtained CE-IVD marking for Allplex™ Vaginitis Screening Assay 2019.03.25
home > News > Product news